Opexa Therapeutics is a biopharmaceutical company that develops personalized cellular therapies for the treatment of multiple sclerosis. Based on the company’s own T-cell technology, its leading product candidates have been through clinical trials to test their effectiveness in treating patients with secondary progressive MS. The company, formerly PharmaFrontiers Corp., has been in operation since 2003. For more information, please visit the company’s website at www.opexatherapeutics.com.